CG Oncology

Historical price data

CG Oncology is a publicly traded, late-stage biopharma company singularly dedicated to transforming the treatment landscape for bladder cancer patients. Its core asset, cretostimogene grenadenorepvec, is an engineered oncolytic immunotherapy with a dual mechanism of action designed to selectively destroy cancer cells and stimulate a systemic anti-tumor immune response. The company is advancing this candidate through a pivotal Phase 3 program (PIVOT-006) for BCG-unresponsive NMIBC, with the goal of establishing it as a new backbone, bladder-sparing therapeutic. Backed by experienced leadership and investors, CG Oncology is positioned as a potential leader in urologic oncology.

Engineered oncolytic immunotherapy platform based on an intravesically delivered adenovirus designed for selective replication in cancer cells and stimulation of a systemic anti-tumor immune response.

8 drugs in pipeline, 3 in Phase 3

Total raised: $618M

Main competitors include approved therapies for BCG-unresponsive NMIBC like nadofaragene firadenovec (Adstiladrin) and pembrolizumab (Keytruda). CG Oncology differentiates with cretostimogene's oncolytic immunotherapy mechanism, designed for direct tumor lysis and immune activation via intravesical delivery, positioning it as a potential backbone treatment with a favorable tolerability profile.